Batm Advanced Communicat... Share Discussion Threads

[kooba] 06/9/2022 15:06

Activists very often use the media and social media to put pressure on companies they are invested in…normal course of events. Yep they can call a general meeting ( no longer termed an Extraordinary GM if they have 5%) but it’s a route normal institution often takes and never seen LO being that aggressive. So why anyone is talking about what an activist might do ..first we would need to see an activist taking a declared interest to be able to pull any levers.
Sale and leaseback of small properties is not going to create any real value ..how much would that bring in? Its also a strategy for asset heavy companies who need finance not asset light companies who have declared to have excess cash.

Great to know these unquestionable facts “What makes this kind of scenario particularly relevant for BATM is because the shares are so very cheap, while the balance sheet is absolutely pristine. “


As to the ..its not the real rat dialogue .. just contact them and ask something only the blog writer would know..the usual dismissal of anything you don’t like as fake fraud whatever if it doesn’t suit and it is or isnt the RAT or it’s definitely me that is the RAT is just weird , if anyone wants to shut down their accusations then engage and show them you know better ..if you have the stones that is.

Whoever it is and i will repeat for the sake of any doubt that is continually cast with zero basis…it ain’t me , they left their email if you want to call them names and challenge anything directly ..knock yourselves out.
From post by STR
“My email address is shiftytherat at proton mail dot com”

[pockstones] 06/9/2022 14:40

Dear Echoridge,
Good luck with being activist in a business such as Batm
Chance of success slim to none and heavy on the none I suggest

[emeraldzebra] 06/9/2022 13:36

BEST of luck to all.

[emeraldzebra] 06/9/2022 13:36

Dear Echo, Thanks vm indeed for such a detailed and informative reply. Really appreciated. And

[echoridge] 06/9/2022 13:19

So, couple of things, Emerald. First off, I agree with you that the 'rat' here was likely phoney. Regardless, it backfired on whomever it was as the response from multiple posters was quicker and more substantive than they could have imagined and genuine shareholders have benefited from the extra information, while exposing others as intellectually and ethically compromised, to put it mildly. As to your interest in possible communications between the Company and major institutional shareholders (not sure L&G is a material holder anymore, but perhaps you meant Lombard Odier) however, you must realise that these institutional shareholders are independent companies and have never and would never share with the market - or permit the Company to do so either - any 'representations' they may have made to the Company (and/or the response). That's just the way it is unfortunately. However, one obvious exception to that of course, would be if one of those instos initiates something more 'hostile' with the Company where the former proposes strategies to create shareholder value but the Company formally rejects them. In that event, the institution involved might decide to take a more public approach and try and call an EGM with their proposed corporate actions on the agenda, etc. In such a situation, the now-activist institution may well include in their public releases, summaries of conversations they've had with management and why they feel the Company has been unreasonable in their position opposing such actions. What makes this kind of scenario particularly relevant for BATM is because the shares are so very cheap, while the balance sheet is absolutely pristine. As a result, if management wish, or they are 'encouraged', they could pursue anything from levering up the balance sheet a bit, to a sale-leaseback of one or both of their properties in Boston and/or Rome, to of course, even selling one of their main businesses in order to create a more focused enterprise, and then return some or all of that cash to shareholders. And that's before even re-engaging the buyback, which I believe is still likely. In BATM shares, you have the kind of real asset/deep undervaluation combined with the means to extract it, that make a perfect activist backdrop. All we need, as ever, is for management to demonstrate the will to act, but if they don't or won't, hopefully we've reached the point - after months of index rebalance selling and the needless radio silence from management - where, as you've suggested, larger shareholders may be inclined to give them a bit more of a push in that direction.

[kooba] 06/9/2022 10:10

He's probably doing the roadshow ..hopefully not recommending a pairs trade against Nanoco...still holding !

[kemche] 06/9/2022 08:52

Once Barry has done the rounds in the city then the whooshing can begin in earnest.

[emeraldzebra] 06/9/2022 08:48

Revisiting old ground, ....but i should dearly like to know what questions and representations have been made to the company by the very large share holders such as L and G, and what - if anything - they received from the Co.in return. Let's hope this is the bottom of the trading range though. Fingers crossed. I do not possess anything like the business intellect of the majority on this board, but somehow i don't think the 'Rat' on this board is the real one, but somebody posing as him for a bit of fun.

[kemche] 05/9/2022 15:23

Classic Passover and index reshuffling at play.

Where's Barry? Hedge fund conference?

[pockstones] 03/9/2022 20:19

Dear FSE,
I made no comment about Adaltis on August 4 I merely posed the question at what share price will holders accept that they have been misled
The price continues to fall and the allegations made by Shifty the Rat remain unanswered
Which makes your by return responses all the more questionable

[kooba] 03/9/2022 17:42

Pockstones I think you will find you do not have suitable qualifications according to FSE to have an opinion as to whether you feel misled in any way. I certainly feel misled around the share buy back ..I'm pretty sure I'm qualified to air that opinion...but I bet I'm not as i haven't filed a full cv with him. Baaah

[fse] 03/9/2022 16:14

pockstones just as an example of straying over to the unacceptable you said this on August 4th posted below with no proof or substance of any kind to back up your statement

August 4th.pockstones..... At what share price one wonders will holders accept that they have been misled?

that and comments that Adaltis are withholding accounts (which they are not) are low blows to investors.
Sure you can probably get away with lying to support an agenda because unless someone actually brings a case against you your lie will sit there.
Because you can get away with something does not mean its correct and it's certainly not an honest report or service to your fellow man.

[fse] 03/9/2022 16:00

So Pockstones you admit that there is nothing wrong with the accounts other than there might be simply because the company does not reply to an inaccurate blog.
Its hard enough for investors to look objectively at individual companies and the background they are trading in.
It is fraudulent to spread false information for the purpose of self enrichment.
Lying about something is not hard evidence.
Not responding to spurious unfounded allegations does not signify guilt.

I asked you this.....

"Please post the unanswered questions on governance that you have.
What are they ?

Let's have some hard evidence from you seeing as you claim impropriety."

[pockstones] 03/9/2022 15:40

Dear FSE,
The hard evidence is the fall in value and the silence of management if you have something to hide do not give your accusers the oxygen of publicity.
Your Cyclopian approach and lengthy blurbs suggest a connection which adds to your general implausibility

[kooba] 03/9/2022 12:06

An interesting read for those with or without scientific qualifications in telecommunications and computer science.https://www.ispreview.co.uk/index.php/2022/07/cityfibre-uk-pilot-ucpe-universal-customer-premises-equipment.html

[fse] 02/9/2022 22:43

pockstones the share price started falling long before the rat showed up on the scene largely due to the misconception that Adaltis and BATM medical was a Covid company and when the pandemic ended their business would dry up and growth lost.
To a point thats true and if you bought for that and many did you need to exit and find the next high roller.
The Russell Index was the catalyst to get a good short going and in that respect it was very successful.
But you are saying that the company is not sound.
The auditors Deloitte & Touche should be castigated.
Please post the unanswered questions on governance that you have.
What are they ?

Lets have some hard evidence from you seeing as you claim inpropriety.

[fse] 02/9/2022 22:25

Its worth looking at the inflection points along the way when looking at the BioMed revenue.At the present time that accounts for most of BATM revenue as a whole as the networking division has been in a developmental stage and is only starting to contribute any revenue at all. Thats a situation thats set to change.
Not matter the hiatus is about weak H1 22 bio med revenue.
Is it weak or is it actually very much going to plan.


From 2012 to 2018 revenue was pretty static rose from 49.1M 2012 to 62.1M 2018
Two major inflection points (unrelated) happened.
First is the move into molecular Diagnostics with Adaltis and an undertaking to take these platforms a lot further with the investment in ADOR
2019 revenue came in at 64.4M (just pre covid period)

Next inflection point was Covid and the related tests which Adaltis were in a position to immediately come up with something as this was the new field they were operating in.

2020 revenue jumped literally doubled to 128.7M (a large part of this are covid tests but the other tests made possible by Adaltis and highlighted by the pandemic are also gaining revenue)

2021 revenue is slightly down at 112M (the best of the covid test revenue is past and whats available are at much lower margins. Non Covid tests had to significantly increase to make up the numbers)

2022 H1 revenue came in @48M with FY estimates in the 108M range. H1 revenue simply could not have come in at these levels unless non covid molecular tests contribute the lions share of revenue because covid tests have dropped off the radar.

Revenue numbers are not the most important thing to watch here its where it comes from.
The development and now actual sales of Molecular Diagnostic tests, hardware and solutions plus the development of next age solutions like the RCA diagnostic platform are now achieving sales
Telco systems sells SFA amount of kit at the moment because its morphed into a totally different filed which they are achieving first sales in.

These new areas of business revenue started to be noticed @2018 Bio Med and 2022 for Telco.
Its not jam tomorrow anymore they will either deliver or not but they do have the products and solutions in play and for sale.
The markets either don't understand this or don't want to believe it.

[pockstones] 02/9/2022 22:00

FSE Shifty the Rat has raised unanswered governance issues around this company which has fallen from over a pound to current levels if there was not truth in the matters raised the market price would not have fallen
Asking for someone’s qualifications is ridiculous if you think the company is sound keep buying and get yourself an expensive education in common sense

[fse] 02/9/2022 20:01

This is a snapshot of the Bio med division H1/22 just reported.
Revenue falls were all from this sector due to winding down of Covid Tests which they anticipated when they published FY 21.
All the rest of the divisions posted firmer results.


Bio-Medical Division (77% of total revenue)
• Revenue was $44.4m (H1 2021: $55.1m); on a constant currency basis, revenue was $48.0m
• Diagnostics Unit
o Sales increased of molecular diagnostic products not related to COVID-19, which was offset by market-wide reduction in prices, as well as lower demand, for COVID-19 products as the global pandemic subsided
o New multi-respiratory test was CE registered with initial sales expected to commence in Q4 2022 o Progressed development of new tuberculosis test kit, which was CE approved, alongside Stop TB
Partnership, an international alliance
o Opened new state-of-the-art diagnostics laboratories and facilities in Italy and Israel to support the
activity of ADOR Diagnostics (“ADOR”), which is developing its proprietary isothermal diagnostic
solution
o ADOR received an additional $10m of investment, of which the Group contributed $4m (giving the
Group an increased shareholding of 37.2%)
• Eco-Med Unit
o Accelerated progress, with the finalisation of two projects for delivery of the Group’s ISS AGRI
solution and construction advanced on two further installations
• Distribution Unit
o Increased sales from greater volume of regular business

[fse] 02/9/2022 19:47

Thats not what I said is it Kooba.
Whats your question ?

[fse] 02/9/2022 18:45

kooba ... blah blah blah
I had a go at you because.........
You made comments that Adaltis had failed to file certain accounts.
Suddenly a new rat avatar shows up on the scene and you are sharing screen shots.
Now you say you are not calling anything untoward
You say you made no effort to contact the CFO as you knew they would not reply to you.
Would it not be better to contact BATM and then if you did not receive a reply post the info on here like car1pet did, its lends credibility to your case.

We are all extremely upset about the current share price for BATM. It does not reflect progress the company has clearly been making.

BATM develop IP to market introduction point they are not manufacturers per se.
The latest set of results were from an extremely difficult period for all companies but the underlying growth on sustainable "new" product continued.
The last period followed on from FY results that included the sale of NGSoft so profits were down by that amount as expected.

Adaltis reported winding down of Covid test kits which was a sizeable non repeatable segment. They also reported that increased sales of non Covid tests would soon replace the amount lost by Covid departure. If you look at the Bio Med figures its clear this is the case.

As I have already commented if you allow for these two factors and the very real incidence in reporting in $US. Then the situation looks rather different.

BATM and Shore Capital have expressed that they expect BATM to meet expectation (which were only marginally lowered) for full year.

The other factor here is that BATM have migrated away from the legacy business and revenue that is now flowing in is from "new solution" business.
At this stage what we should be looking for is this trend to continue.
Last results showed just that.

Basically what I am saying is that the company itself is making very solid progress in getting to where they want to be on the development scale.
Future revenue will come through increased sales and principally licensing.

BATM were hit by a perfect storm of unrelated events thats for certain .
But I do share frustration with is how the company and advisors handled this period and their silence on this matter caused a bunch of unsubstantiated inuendo and we are where we are today.

The company is at a very major inflection point where they are now marketing what they have developed. Lack of substantial revenue does not at this stage = lack of progress.

[kooba] 02/9/2022 17:55

If i get attacked and called i liar i tend not to ignore it..just one of those things i guess. You can of course ignore me ..it's what that button is for.